Clinical Obesity最新文献

{"title":"Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort","authors":"Emiliano G. Manueli Laos,&nbsp;Andres Fontaine-Nicola,&nbsp;Bianca Serafica,&nbsp;Lily Zhang,&nbsp;Brian T. Layden,&nbsp;Reed Berger,&nbsp;Carlos Agustin Orda,&nbsp;Francisco Schlottmann,&nbsp;Amber Pirzada,&nbsp;Mario A. Masrur","doi":"10.1111/cob.70116","DOIUrl":"https://doi.org/10.1111/cob.70116","url":null,"abstract":"<div>\u0000 \u0000 <p>While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight reduction, yet most clinical trials lack ethnic diversity, limiting the generalizability of these outcomes. This is a retrospective, single-centre study that evaluates 12-month weight loss results comparing tirzepatide and SG within a diverse, urban patient population. 12-month weight loss outcomes were compared between patients receiving tirzepatide and those undergoing sleeve gastrectomy (SG). Primary endpoints included changes in BMI, excess weight loss and total weight loss (TWL) percentage at 3, 6 and 12 months, following ASMBS reporting standards to evaluate treatment efficacy and comparative outcomes. Linear mixed models revealed statistically significant differences in weight loss between SG and tirzepatide cohorts across all time points (<i>p</i> &lt; 0.001). By 12 months, the SG group was associated with greater weight loss than tirzepatide in this selected matched cohort with a 30% TWL and a 12 kg/m² BMI reduction, compared to 12% TWL and 7 kg/m² for tirzepatide. SG was associated with greater weight loss than tirzepatide in this selected matched cohort, especially for eligible patients in ethnic minority groups. However, tirzepatide serves as a vital non-invasive alternative, requiring individualized treatment decisions based on patient preference, cost and specific metabolic goals.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149125871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoedema and Obesity Misclassification: A Phenotype Based Approach to Cardiometabolic Risk Beyond Body Mass Index","authors":"Ron T. Varghese,&nbsp;Diana G. Varghese","doi":"10.1111/cob.70115","DOIUrl":"10.1111/cob.70115","url":null,"abstract":"<p>Lipoedema is a painful adipose tissue disorder marked by disproportionate limb fat and often misclassified as generalized obesity or lymphoedema. This review examines its metabolic phenotype and implications for cardiometabolic assessment and management. PubMed/MEDLINE was searched from inception through May 2026 for studies on lipoedema, obesity, body composition, metabolic risk, insulin resistance, diabetes, lifestyle interventions, pharmacotherapy and liposuction. Relevant clinical, mechanistic, review and consensus literature was narratively synthesized. Evidence is limited and heterogeneous, consisting mainly of observational cohorts, referral-centre series, mechanistic studies and consensus guidance, predominantly involving women. Some studies report fewer metabolic abnormalities in women with lipoedema than in women with BMI-matched lifestyle-related overweight or obesity. These findings do not establish metabolic protection and may reflect differences in central adiposity, disease stage, diagnostic criteria, body composition, inflammation or referral patterns. Obesity and glucose-lowering therapies, including glucagon-like peptide-1 receptor agonists, remain appropriate for established indications, but direct modification of lipoedema has not been demonstrated. Cardiometabolic risk in lipoedema should be assessed using a phenotype-based approach that distinguishes painful limb adiposity from central and ectopic fat while considering age, sex, menopausal status and established risk factors. BMI should be interpreted with waist measures, metabolic screening, body composition and muscle mass when relevant. Prospective studies using standardized diagnostic criteria, direct measures of insulin sensitivity, detailed body composition and clinically meaningful outcomes are needed to clarify long-term risk and distinguish lipoedema biology from coexisting central obesity.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘The Neurological Impact of Metabolic and Bariatric Surgery: A Systematic Review of Post-Operative Neuropathic and Non-Neuropathic Complications’","authors":"","doi":"10.1111/cob.70114","DOIUrl":"10.1111/cob.70114","url":null,"abstract":"&lt;p&gt; &lt;span&gt;S. Thirumalai&lt;/span&gt;, &lt;span&gt;G. Balamurugan&lt;/span&gt;, &lt;span&gt;S. Jagdale&lt;/span&gt;, et al., “ &lt;span&gt;The Neurological Impact of Metabolic and Bariatric Surgery: A Systematic Review of Post-Operative Neuropathic and Non-Neuropathic Complications&lt;/span&gt;,” &lt;i&gt;Clinical Obesity&lt;/i&gt; &lt;span&gt;16&lt;/span&gt;, no. &lt;span&gt;5&lt;/span&gt; (&lt;span&gt;2026&lt;/span&gt;): e70102. https://doi.org/10.1111/cob.70102.&lt;/p&gt;&lt;p&gt;The following references should be listed as follows:&lt;/p&gt;&lt;p&gt;Reference 11&lt;/p&gt;&lt;p&gt; &lt;span&gt;E. Eruyar&lt;/span&gt; and &lt;span&gt;O. Banli&lt;/span&gt;, “ &lt;span&gt;Neurological Complications After Bariatric Surgery in Turkish People&lt;/span&gt;,” &lt;i&gt;SN Comprehensive Clinical Medicine&lt;/i&gt; &lt;span&gt;3&lt;/span&gt;, no. &lt;span&gt;9&lt;/span&gt; (&lt;span&gt;2021&lt;/span&gt;): &lt;span&gt;949&lt;/span&gt;–&lt;span&gt;954&lt;/span&gt;. https://doi.org/10.1007/s42399-021-00789-4.&lt;/p&gt;&lt;p&gt;Reference 12&lt;/p&gt;&lt;p&gt;\u0000 &lt;span&gt;K. Kim&lt;/span&gt;, &lt;span&gt;T. J. Oh&lt;/span&gt;, &lt;span&gt;Y. S. Park&lt;/span&gt;, et al., “ &lt;span&gt;Association Between Fat Mass or Fat Fibrotic Gene Expression and Polyneuropathy in Subjects With Obesity: A Korean Metabolic Bariatric Surgery Cohort&lt;/span&gt;,” &lt;i&gt;Frontiers in Endocrinology (Lausanne)&lt;/i&gt; &lt;span&gt;13&lt;/span&gt;, (&lt;span&gt;2022&lt;/span&gt;): 881093.\u0000 &lt;/p&gt;&lt;p&gt;Reference 18&lt;/p&gt;&lt;p&gt;\u0000 &lt;span&gt;A. Alsabah&lt;/span&gt;, &lt;span&gt;S. Al Sabah&lt;/span&gt;, &lt;span&gt;S. Al-Sabah&lt;/span&gt;, et al., “ &lt;span&gt;Investigating Factors Involved in Post Laparoscopic Sleeve Gastrectomy (LSG) Neuropathy&lt;/span&gt;,” &lt;i&gt;Obesity Surgery&lt;/i&gt; &lt;span&gt;27&lt;/span&gt;, no. &lt;span&gt;5&lt;/span&gt; (&lt;span&gt;2017&lt;/span&gt;): &lt;span&gt;1271&lt;/span&gt;–&lt;span&gt;1276&lt;/span&gt;.\u0000 &lt;/p&gt;&lt;p&gt;Reference 19&lt;/p&gt;&lt;p&gt; &lt;span&gt;F. D. Machado&lt;/span&gt;, &lt;span&gt;O. H. Nienov&lt;/span&gt; and &lt;span&gt;H. Schmid&lt;/span&gt;, “ &lt;span&gt;Prevalence of Peripheral Polyneuropathy Before and After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy&lt;/span&gt;,” &lt;i&gt;Obesity Surgery&lt;/i&gt; &lt;span&gt;31&lt;/span&gt;, no. &lt;span&gt;10&lt;/span&gt; (&lt;span&gt;2021&lt;/span&gt;): &lt;span&gt;4427&lt;/span&gt;–&lt;span&gt;4435&lt;/span&gt;. https://doi.org/10.1007/s11695-021-05606-4.&lt;/p&gt;&lt;p&gt;Reference 21&lt;/p&gt;&lt;p&gt;\u0000 &lt;span&gt;S. Abdulrazzaq&lt;/span&gt;, &lt;span&gt;W. El Ansari&lt;/span&gt; and &lt;span&gt;T. F. Al-Ahbabi&lt;/span&gt;, “ &lt;span&gt;Effect of COVID-19 Pandemic on Hospital Admission Rates of Patients With Malnutrition and/or Neuromuscular Complications After Bariatric Surgery&lt;/span&gt;,” &lt;i&gt;Neurosciences (Riyadh)&lt;/i&gt; &lt;span&gt;27&lt;/span&gt;, no. &lt;span&gt;3&lt;/span&gt; (&lt;span&gt;2022&lt;/span&gt;): &lt;span&gt;164&lt;/span&gt;–&lt;span&gt;174&lt;/span&gt;.\u0000 &lt;/p&gt;&lt;p&gt;Reference 22&lt;/p&gt;&lt;p&gt;\u0000 &lt;span&gt;M. Riccò&lt;/span&gt;, &lt;span&gt;C. Rapacchi&lt;/span&gt;, &lt;span&gt;A. Romboli&lt;/span&gt;, et al., “ &lt;span&gt;Peripheral Neuropathies After Bariatric Surgery. Preliminary Results From a Single-Centre Prospective Study in Northern Italy&lt;/span&gt;,” &lt;i&gt;Acta Biomedica&lt;/i&gt; &lt;span&gt;90&lt;/span&gt;, no. &lt;span&gt;3&lt;/span&gt; (&lt;span&gt;2019&lt;/span&gt;): &lt;span&gt;259&lt;/span&gt;–&lt;span&gt;265&lt;/span&gt;.\u0000 &lt;/p&gt;&lt;p&gt;Reference 23&lt;/p&gt;&lt;p&gt;\u0000 &lt;span&gt;M. Alligier&lt;/span&gt;, &lt;span&gt;A. L. Borel&lt;/span&gt;, &lt;span&gt;V. Savey&lt;/span&gt;, et al., “ &lt;span&gt;A Series of Severe Neurologic Complications After Bariatric Surgery in France: The NEUROBAR Study&lt;/span&gt;,” &lt;i&gt;S","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148966923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis","authors":"Difei Lu,&nbsp;Na Li,&nbsp;Zhenfang Yuan,&nbsp;Ying Gao","doi":"10.1111/cob.70112","DOIUrl":"10.1111/cob.70112","url":null,"abstract":"<div>\u0000 \u0000 <p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual agonists have become pivotal options for obesity, but marked weight loss heterogeneity remains poorly understood. This meta-regression analysis aimed to identify factors influencing this heterogeneity. We searched Medline, Embase, The Cochrane Library, and Web of Science up to February 1, 2026, enrolling 32 eligible trials (40 408 participants) following PRISMA guidelines. Meta-regression and subgroup analyses were performed using R software. Pooled analysis showed that GLP-1RAs and dual agonists achieved a weighted mean weight reduction of 9.36% (95% CI 7.92%–10.80%), with high interstudy heterogeneity (<i>I</i>² = 99.6%, <i>p</i> &lt; 0.001). Subgroup analyses revealed that GLP-1/GIP dual agonists (tirzepatide) and longer treatment duration (≥ 72 weeks) yielded superior weight-lowering effects. Meta-regression demonstrated that baseline anxiety/depression was positively associated with weight loss efficacy (<i>β</i> = 2.44, <i>p</i> &lt; 0.001, <i>R</i>² = 81.34%). Comorbid Type 2 diabetes mellitus (T2DM), obstructive sleep apnea (OSA) and metabolic dysfunction-associated fatty liver disease (MAFLD) were negatively correlated with treatment response (all <i>p</i> &lt; 0.05). Emotional state and metabolic comorbidities including T2DM, OSA and MAFLD are important influencing factors of the interindividual differences of weight loss efficacy of GLP-1RAs and dual agonists, providing evidence for personalized obesity management.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Obesity Management Education for Healthcare Professionals: A Rapid Review and Meta-Analysis","authors":"Rebecca Wu,&nbsp;Srividya Adapa,&nbsp;Maria Agaliotis,&nbsp;Samantha Hocking,&nbsp;Evan Atlantis","doi":"10.1111/cob.70113","DOIUrl":"https://doi.org/10.1111/cob.70113","url":null,"abstract":"<p>Healthcare professionals (HCPs) play a critical role in obesity management, yet many report inadequate training, low confidence and stigma-related attitudes. While education programmes have been developed to address these issues, evidence of their effectiveness remains mixed. This study aimed to evaluate the effectiveness of structured education and training programmes in improving HCPs' practice competencies in obesity management. We searched MEDLINE, EMBASE, CINAHL, Web of Science, ERIC and Google Scholar for studies published from 2020 assessing structured obesity management education programmes for HCPs. Eligible studies reported outcomes related to practice competencies (knowledge, skills and practice behaviours, confidence, attitudes) or patient outcomes (weight loss). Standardised mean differences (SMDs) were pooled using random-effects meta-analysis. Heterogeneity was assessed using <i>I</i>² and <i>Q</i> statistics, and subgroup analyses explored potential sources. Studies not included in the meta-analysis were summarised descriptively. Eighteen studies were included from 1683 records. Pooled analysis of four RCTs and three non-RCTs showed a significant improvement in practice competencies (SMD = 0.41, 95% CI 0.12–0.70, <i>p</i> &lt; 0.01) with high heterogeneity (<i>I</i>² = 60%). Effects were significant in RCTs (SMD = 0.53, 95% CI 0.10–0.95, <i>p</i> = 0.01), but not non-RCTs (SMD = 0.25, 95% CI −0.04 to 0.55, <i>p</i> = 0.09). Interventions lasting ≥ 4 h produced larger, significant effects (SMD = 0.68, 95% CI 0.30–1.07, <i>p</i> &lt; 0.01), while shorter interventions did not. Quasi-experimental studies supported improvements across HCP competencies and occasionally, patient outcomes. Structured education and training programmes may improve HCP competencies in obesity management, particularly confidence, with stronger effects generally observed in longer, more comprehensive interventions (≥ 4 h).</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cob.70113","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IMPROVE 2025: The 3rd International Meeting on Pathway-Related Obesity: Vision & Evidence","authors":"Jesús Argente,&nbsp;Erica L. T. van den Akker,&nbsp;Metin Cetiner,&nbsp;Karine Clément,&nbsp;Elizabeth Forsythe,&nbsp;Alastair Garfield,&nbsp;Peter Kühnen,&nbsp;Gabriel Ángel Martos-Moreno,&nbsp;David Meeker,&nbsp;Hermann L. Müller,&nbsp;Hanneke M. van Santen,&nbsp;Julia von Schnurbein,&nbsp;Bérénice Segrestin,&nbsp;Tomohiro Tanaka,&nbsp;Manuel Tena-Sempere,&nbsp;Martin Wabitsch,&nbsp;Stefanie Zorn,&nbsp;I. Sadaf Farooqi","doi":"10.1111/cob.70109","DOIUrl":"10.1111/cob.70109","url":null,"abstract":"<p>An international cohort of 161 clinicians and researchers from 19 countries attended the 3rd International Meeting on Pathway-Related Obesity: Vision &amp; Evidence (IMPROVE) in Prague, Czech Republic, on 2–4 July 2025. The aims of the meeting were to advance understanding of hyperphagia and obesity caused by defects in the melanocortin-4 receptor (MC4R) pathway and to support peer-to-peer sharing of clinical experience and emerging evidence. The programme comprised four sessions covering hyperphagia, monogenic MC4R pathway diseases, Bardet–Biedl syndrome and acquired hypothalamic obesity. Discussions focused on defining and measuring hyperphagia, updates in genetic diagnostics and natural history, real-world and trial data on targeted therapies and practical multidisciplinary models of care with earlier intervention. Patient and caregiver quality of life remained central throughout. These Proceedings summarise the key updates, discussions and initiatives generated at IMPROVE 2025.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cob.70109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148929147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Bariatric Surgery on Improvement of Retinal Microvasculature in Patients With Obesity: A Systematic Review and Meta-Analysis","authors":"Syifa Salsabila,&nbsp;Wilbert Huang,&nbsp;Aklila Qurrota A’ini Sumardi,&nbsp;Lisa Milena Anabela,&nbsp;Alfi Alfisa Aji","doi":"10.1111/cob.70110","DOIUrl":"10.1111/cob.70110","url":null,"abstract":"<div>\u0000 \u0000 <p>Obesity is associated with adverse retinal microvascular changes, including narrower central retinal arteriolar equivalent (CRAE), wider central retinal venular equivalent (CRVE) and lower arteriovenous ratio (AVR). Although bariatric surgery improves cardiometabolic risk, its effect on retinal microvascular calibre remains uncertain. We systematically searched the Cochrane Library, PubMed, ScienceDirect and Scopus up to June 2026. Prospective cohort studies reporting CRAE, CRVE or AVR before and after bariatric surgery in patients with obesity were included. Risk of bias was assessed using the Newcastle–Ottawa Scale. Pooled mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. Eight prospective cohort studies including 283 patients were included. Seven studies contributed to the CRAE and CRVE analyses, and seven contributed to the AVR analysis. Bariatric surgery was associated with a significant increase in CRAE (MD = +4.02 μm, CI [0.26–7.78], <i>p</i> = 0.04). Sensitivity analysis excluding one study showed a stronger and more consistent effect (MD = +5.41 μm, CI [4.59–6.22], <i>p</i> &lt; 0.01). CRVE significantly decreased after surgery (MD = −6.75 μm, CI [−7.42 to −6.07], <i>p</i> &lt; 0.01), while AVR significantly increased (MD = +0.03, CI [0.02–0.05], <i>p</i> &lt; 0.01). Sensitivity analyses suggested that the direction of effect was generally robust, although between-study heterogeneity was present. Bariatric surgery may be associated with favourable retinal microvascular changes in patients with obesity, reflected by increased CRAE and AVR and decreased CRVE.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148929162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies","authors":"Giovanna Pagani Paccola,&nbsp;Roberta Fernandes de Oliveira,&nbsp;Matheus Menão Mochetti,&nbsp;Fernanda Pataro Marsola Razera,&nbsp;Rafael Vecchi,&nbsp;Renan Canale Peres Montanher","doi":"10.1111/cob.70111","DOIUrl":"10.1111/cob.70111","url":null,"abstract":"<p>This systematic review and meta-analysis aimed to compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity. We included randomised controlled trials and observational studies comparing tirzepatide and semaglutide with ≥ 24 weeks of follow-up. The primary outcome was percentage weight change from baseline. Secondary outcomes included absolute weight change, weight-loss thresholds, HbA1c and safety outcomes. Ten studies including 41 381 participants were analysed. Tirzepatide was associated with greater percentage weight reduction than semaglutide (MD −4.28 percentage points; 95% CI −5.28 to −3.28; <i>p</i> &lt; 0.00001) and greater absolute weight loss (MD −4.43 kg; 95% CI −5.56 to −3.30; <i>p</i> &lt; 0.00001). Tirzepatide was also associated with a higher likelihood of achieving ≥ 10%, ≥ 15% and ≥ 20% weight loss, with no difference at ≥ 5%. HbA1c reduction was greater with tirzepatide (MD −0.29%; <i>p</i> = 0.0002). Subgroup analyses by study design and type 2 diabetes status yielded consistent findings. There was no significant difference in treatment discontinuation due to adverse events (RR 1.28; <i>p</i> = 0.54), whereas serious adverse events were more frequent with tirzepatide (RR 1.83; <i>p</i> = 0.007). Overall and gastrointestinal adverse events were similar between groups. Tirzepatide was associated with greater weight reduction, greater glycaemic benefit and a higher likelihood of achieving weight-loss thresholds than semaglutide, but with a higher risk of serious adverse events.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13527552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Definition and Diagnostic Criteria of Clinical Obesity—Implications for Metabolic Bariatric Surgical Practice","authors":"Anne J. Brouwer,&nbsp;Guusje Vugts,&nbsp;Ronald S. L. Liem,&nbsp;Simon W. Nienhuijs","doi":"10.1111/cob.70107","DOIUrl":"https://doi.org/10.1111/cob.70107","url":null,"abstract":"","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity Staging Should Explicitly Address Psychotropic Treatment in Severe Mental Illness: A Taiwan Perspective","authors":"Lien-Chung Wei","doi":"10.1111/cob.70108","DOIUrl":"https://doi.org/10.1111/cob.70108","url":null,"abstract":"","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}